This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by van der Kraaij, A. M. Articles by Koster, J. F. Search for Related Content PubMed PubMed Citation Articles by van der Kraaij, A. M. Articles by Koster, J. F.

Circulation, Vol 78, 442-449, Copyright © 1988 by American Heart Association

ARTICLES

Iron-load increases the susceptibility of rat hearts to oxygen reperfusion damage. Protection by the antioxidant (+)-cyanidanol-3 and deferoxamine

AM van der Kraaij, LJ Mostert, HG van Eijk and JF Koster
Eramus University, Department of Biochemistry, Rotterdam, The Netherlands.

To investigate whether iron is involved in the reperfusion syndrome by aggravating free radical injury, the hearts from iron-loaded and control rats were perfused under normoxic, anoxic, and reperfusion conditions. Normoxic perfusion revealed no change in coronary flow, contractility, or lactate dehydrogenase (LDH) release between these two groups. Under anoxic and reperfusion conditions, however, we found a significant increase of ventricle fibrillation (56% vs. 0%, p less than 0.01, n = 9), a significantly lower recovery of contractility (21 +/- 7.4% vs. 81 +/- 6.6%, mean +/- SEM; p less than 0.001), and a significant increase of LDH release (667 +/- 142 vs. 268 +/- 37 mU LDH/min/g wet wt, mean +/- SEM; p less than 0.05). Administration of either 20 microM of the antioxidant (+)-cyanidanol-3 or 50 microM of the iron-chelator deferoxamine totally prevented the generation of ventricle fibrillation and normalized contractility to control levels in the iron-loaded group. Moreover, 20 microM (+)-cyanidanol-3 significantly lowered LDH release in this period (312 +/- 67 mU), whereas deferoxamine had no protective effect on this LDH release (1,494 +/- 288 mU). Normal hearts appeared to be protected by 20 microM (+)-cyanidanol-3 as well. In this group (n = 6), a significantly higher recovery of contractility (97.1 +/- 3.2% vs. 81 +/- 6.6%, p less than 0.05) and a significantly lower release of LDH (110 +/- 27 vs. 268 +/- 37 mU, p less than 0.05) was found compared with the control group (n = 9). No difference in superoxide dismutase or glutathione peroxidase activity was found between the groups.(ABSTRACT TRUNCATED AT 250 WORDS)

This article has been cited by other articles:

				D. L. van der A, J. J.M. Marx, D. E. Grobbee, M. H. Kamphuis, N. A. Georgiou, J. H. van Kats-Renaud, W. Breuer, Z. I. Cabantchik, M. Roest, H. A.M. Voorbij, et al. Non-Transferrin-Bound Iron and Risk of Coronary Heart Disease in Postmenopausal Women Circulation, April 25, 2006; 113(16): 1942 - 1949. [Abstract] [Full Text] [PDF]

				J. H. Kramer, S. B. Murthi, R. M. Wise, I-T. Mak, and W. B. Weglicki Antioxidant and lysosomotropic properties of acute d-propranolol underlies its cardioprotection of postischemic hearts from moderate iron-overloaded rats. Experimental Biology and Medicine, April 1, 2006; 231(4): 473 - 484. [Abstract] [Full Text] [PDF]

				D. L. van der A, P. H.M. Peeters, D. E. Grobbee, J. J.M. Marx, and Y. T. van der Schouw Dietary haem iron and coronary heart disease in women Eur. Heart J., February 1, 2005; 26(3): 257 - 262. [Abstract] [Full Text] [PDF]

				A. BESARAB, S. FRINAK, and J. YEE An Indistinct Balance: The Safety and Efficacy of Parenteral IronTherapy J. Am. Soc. Nephrol., September 1, 1999; 10(9): 2029 - 2043. [Full Text]